1. Home
  2. CNS vs RCUS Comparison

CNS vs RCUS Comparison

Compare CNS & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Inc

CNS

Cohen & Steers Inc

N/A

Current Price

$73.50

Market Cap

3.6B

Sector

Finance

ML Signal

N/A

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

N/A

Current Price

$18.47

Market Cap

3.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNS
RCUS
Founded
1986
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.2B
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
CNS
RCUS
Price
$73.50
$18.47
Analyst Decision
Hold
Strong Buy
Analyst Count
3
15
Target Price
★ $69.33
$41.00
AVG Volume (30 Days)
283.3K
★ 2.5M
Earning Date
10-15-2026
11-04-2026
Dividend Yield
★ 3.66%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 2.58
N/A
Revenue
★ $427,536,000.00
$247,000,000.00
Revenue This Year
$9.41
N/A
Revenue Next Year
$5.94
N/A
P/E Ratio
$29.34
★ N/A
Revenue Growth
★ 4.07
N/A
52 Week Low
$58.39
$17.43
52 Week High
$86.56
$31.74

Technical Indicators

Market Signals
Indicator
CNS
RCUS
Relative Strength Index (RSI) 52.88 37.67
Support Level $73.07 $17.97
Resistance Level $77.74 $24.46
Average True Range (ATR) 2.23 1.59
MACD 0.57 0.09
Stochastic Oscillator 56.19 13.41

Price Performance

Historical Comparison
CNS
RCUS

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests primarily in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for nearly two-thirds of its $102.5 billion in managed assets at the end of July 2026. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (25%) of its managed assets (base management fees) from institutional clients, 48% (55%) from open-end funds, and 13% (20%) from closed-end funds.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Share on Social Networks: